神经保护剂：治疗用途与全球市场

全球神经保护剂市场预计将从 2025 年的 439 亿美元成长到 2030 年底的 609 亿美元，预测期（2025-2030 年）的复合年增长率为 6.7%。

预计北美市场将从 2025 年的 182 亿美元增长到 2030 年底的 254 亿美元，在预测期（2025-2030 年）内以 6.9% 的复合年增长率增长。

欧洲市场预计将从 2025 年的 124 亿美元成长到 2030 年底的 168 亿美元，在预测期（2025-2030 年）内以 6.2% 的复合年增长率增长。

本报告考察了全球神经保护剂市场，并提供了市场概况、市场影响因素和市场机会分析、技术趋势、法律制度、市场规模趋势和预测、按各个细分市场和地区进行的详细分析以及主要企业的概况。

目录

第一章执行摘要

• 市场展望
• 调查范围
• 市场概况
• 市场动态与成长要素
• 新兴技术
• 细分市场分析
• 区域分析
• 结论

第二章 市场概览

• 概述
• PESTLE分析
• 波特五力分析

第三章 市场动态

• 概述
• 市场驱动因素
• 全球神经系统疾病发生率上升
• 老年人神经系统疾病盛行率不断上升
• 人们对神经保护剂的认识不断提高
• 市场限制
• 药物研发高成本
• 神经保护产品线临床试验失败
• 市场机会
• 增加医疗保健投资
• 对製药和生物技术公司的战略意义

第四章：监理现状

• 概述
• 美国监管情势
• 欧洲监管情势
• 日本的监理情势
• 其他国家

第五章 新兴科技与发展

• 新兴技术
• 神经系统疾病的精准医疗
• 神经系统疾病的基因疗法
• 神经退化和干细胞疗法
• 神经科学中的奈米技术
• 结论
• 管道分析
• 重点总结
• 专利分析
• 重点总结

第六章 市场区隔分析

• 细分市场分析
• 市场区隔：依适应症划分
• 概括
• 脑血管疾病
• 神经退化性疾病
• 眼科疾病
• 中枢神经系统损伤
• 按治疗类型分類的市场细分
• 概括
• 小分子药物
• 单株抗体
• 细胞疗法
• 基因治疗
• 其他生物技术产品
• 按药物类别分類的市场细分
• 概括
• 免疫反应调节剂
• 抗凝血剂
• 抗血管新生药物
• 抗氧化剂
• 眼内压降低
• 抗失智症药物
• 抗惊厥药
• 溶栓药物
• 帕金森氏症药物
• 反义寡核苷酸
• 抗淀粉样蛋白药物
• 其他神经保护剂
• 地理区域
• 市场区隔：依地区划分
• 概括
• 北美洲
• 欧洲
• 亚太地区
• 南美洲
• 中东和非洲

第七章 竞争讯息

• 重点总结
• 竞争分析
• 策略倡议

第八章 神经保护剂产业的永续性：ESG视角

• 概述
• 永续製药生产的关键策略
• 整合绿色化学
• 能源和资源效率
• 永续原料采购
• 减少废弃物并实施循环经济
• 数位化和智慧製造
• 法规遵从性和绿色认证
• 协作创新和知识共用
• 永续产品生命週期管理
• ESG风险评估
• BCC 的结论

第九章附录

• 调查方法
• 来源
• 简称
• 公司简介
• ABBVIE INC.
• ASTRAZENECA
• BAYER AG
• BIOGEN
• BOEHRINGER INGELHEIM INTERNATIONAL GMBH
• BRISTOL-MYERS SQUIBB CO.
• DAIICHI SANKYO CO. LTD.
• F. HOFFMANN-LA ROCHE LTD.
• GSK PLC.
• LILLY USA LLC.
• MERCK & CO. INC.
• NOVARTIS AG
• SANOFI
• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• UCB SA
• 新兴Start-Ups和市场颠覆者

The global market for neuroprotective agents is expected to grow from $43.9 billion in 2025 and is projected to reach $60.9 billion by the end of 2030, at a compound annual growth rate (CAGR) of 6.7% during the forecast period of 2025 to 2030.

The North American market for neuroprotective agents is expected to grow from $18.2 billion in 2025 and is projected to reach $25.4 billion by the end of 2030, at a CAGR of 6.9% during the forecast period of 2025 to 2030.

The European market for neuroprotective agents is expected to grow from $12.4 billion in 2025 and is projected to reach $16.8 billion by the end of 2030, at a CAGR of 6.2% during the forecast period of 2025 to 2030.

Report Scope

This report presents both qualitative and quantitative data on the current market dynamics and trends in the global neuroprotective agents market. It also assesses pipeline drugs that are under development. The study further includes analyses of various products offered by companies, new strategies implemented by major manufacturers and emerging technologies. It discusses the market prospects for five regions-North America, Europe, Asia-Pacific, South America, and the Middle East and Africa (MEA) and includes profiles of leading companies and their strategies.

This report focuses on different indications, such as neurodegenerative disorders, cerebrovascular disease, ophthalmic diseases and central nervous system (CNS) injuries. It segments neurodegenerative disorders into multiple sclerosis, Alzheimer's disease, epilepsy, Parkinson's disease, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy, and Huntington's disease. Ophthalmic diseases are segmented into age-related macular degeneration, glaucoma and other ophthalmic diseases. Based on drug class, the market is divided into immune response modifiers, blood thinning agents, anti-angiogenic agents, antioxidants, ocular hypotensives, anti-dementia agents, anticonvulsants, thrombolytics, anti-Parkinson's agents, antisense agents, anti-amyloid agents and other neuroprotective agents.

On the basis of therapy type, the overall market is segmented into small molecule drugs, monoclonal antibodies, cell therapies, gene therapies and other biotechnology products. The report also covers market projections throughout 2030 and company profiles. By geography, it is segmented into North America, Europe, Asia-Pacific, the MEA, and South America. North America includes the U.S., Canada, and Mexico; Europe includes Germany, the U.K., France, Italy, Spain, and the Rest of Europe; and Asia-Pacific includes China, India, Japan, and the Rest of Asia-Pacific. The study provides market estimates for 2024, with forecasts for 2025 through 2030.

Report Includes

• 54 data tables and 56 additional tables
• An overview of the global market for neuroprotective agents and their therapeutic applications
• In-depth analysis of global market trends, featuring historical revenue data for 2022-2025, as well as forecasts for 2030. This analysis includes projections of compound annual growth rates (CAGRs) through 2030
• Evaluation of the current market size and revenue growth prospects specific to the neuroprotective agents, accompanied by a market share analysis by therapy type, indication, drug class, and region
• Analysis of current and future demand in the global neuroprotective agents market, along with a detailed analysis of the competitive environment, market regulations and reimbursement practices
• Analysis of drivers, challenges and opportunities affecting market growth
• Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, new product pipeline, regulatory framework and reimbursement scenarios, and ESG trends of the market
• Market share analysis of the key market participants in the neuroprotective agents market, along with their research priorities, product portfolios, global rankings and competitive landscape
• Profiles of major companies within the industry, including Novartis AG, Biogen, Bayer AG, Sanofi, and Teva Pharmaceutical Industries Ltd.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Market Dynamics and Growth Factors
• Emerging Technologies
• Segmental Analysis
• Regional Analysis
• Conclusion

Chapter 2 Market Overview

• Overview
• PESTLE Analysis
• Political Factors
• Economic Factors
• Social Factors
• Technological Factors
• Legal Factors
• Environmental Factors
• Porter's Five Forces Analysis
• Potential for New Entrants (Moderate to Low)
• Bargaining Power of Suppliers (Moderate)
• Bargaining Power of Buyers (Moderate)
• Threat of Substitute Products (Moderate)
• Industry Level of Competitiveness (High)

Chapter 3 Market Dynamics

• Overview
• Market Drivers
• Surge in Neurological Disorders Across the Globe
• Rising Prevalence of Neurological Conditions Among the Elderly
• Rising Awareness for Neuroprotective Agents
• Market Restraints
• High Cost of Drug Development
• Failure of Clinical Trials in the Neuroprotective Product Line
• Market Opportunity
• Rising Healthcare Investments
• Strategic Implications for a Pharmaceutical or Biotech Company

Chapter 4 Regulatory Landscape

• Overview
• Regulatory Scenario in the U.S.
• Regulatory Scenario in Europe
• Regulatory Scenario in Japan
• Other Countries

Chapter 5 Emerging Technologies and Developments

• Emerging Technologies
• Precision Medicine in Neurological Disorders
• Gene Therapy for Neurological Disorders
• Neurodegeneration and Stem Cell Therapy
• Nanotechnology in Neuroscience
• Conclusion
• Pipeline Analysis
• Key Takeaways
• Patent Analysis
• Key Takeaways

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Market Breakdown by Indication
• Takeaways
• Cerebrovascular Disease
• Neurodegenerative Disorders
• Ophthalmic Diseases
• CNS Injury
• Market Breakdown by Therapy Type
• Takeaways
• Small Molecule Drugs
• Monoclonal Antibodies
• Cell Therapies
• Gene Therapies
• Other Biotechnology Products
• Market Breakdown by Drug Class
• Takeaways
• Immune Response Modifiers
• Blood Thinning Agents
• Anti-angiogenic Agents
• Antioxidants
• Ocular Hypotensive
• Anti-Dementia Agents
• Anticonvulsants
• Thrombolytics
• Anti-Parkinson's Agents
• Antisense Agents
• Anti-Amyloid Agents
• Other Neuroprotective Agents
• Geographic Region
• Market Breakdown by Region
• Takeaways
• North America
• Europe
• Asia-Pacific
• South America
• Middle East and Africa (MEA)

Chapter 7 Competitive Intelligence

• Key Takeaways
• Competitive Analysis
• Strategic Initiatives

Chapter 8 Sustainability in Neuroprotective Agents Industry: ESG Perspective

• Overview
• Key Strategies for Sustainable Drug Manufacturing
• Green Chemistry Integration
• Energy and Resource Efficiency
• Sustainable Raw Material Sourcing
• Waste Minimization and Circular Economy Practices
• Digitalization and Smart Manufacturing
• Regulatory Compliance and Green Certification
• Collaborative Innovation and Knowledge Sharing
• Sustainable Product Lifecycle Management
• ESG Risk Ratings
• Concluding Remarks from BCC Research

Chapter 9 Appendix

• Research Methodology
• Sources
• Abbreviations
• Company Profiles
• ABBVIE INC.
• ASTRAZENECA
• BAYER AG
• BIOGEN
• BOEHRINGER INGELHEIM INTERNATIONAL GMBH
• BRISTOL-MYERS SQUIBB CO.
• DAIICHI SANKYO CO. LTD.
• F. HOFFMANN-LA ROCHE LTD.
• GSK PLC.
• LILLY USA LLC.
• MERCK & CO. INC.
• NOVARTIS AG
• SANOFI
• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• UCB S.A.
• Emerging Start-ups/Market Disruptors

List of Tables

• Summary Table : Global Market for Neuroprotective Agents, by Region, Through 2030
• Table 1 : Health Spending, by Country, 2017-2023
• Table 2 : List of Few Clinical Trial Drugs of Parkinson's Disease in Phase 3 and 4, 2025
• Table 3 : List of Few Clinical Trial Drugs for Alzheimer's Disease in Phases 3 and 4, 2025
• Table 4 : List of Few Clinical Trial Drugs for Multiple Sclerosis in Phase 3 and 4, 2025
• Table 5 : List of Few Clinical Trial Drugs for Cerebral Stroke in Phase 3 and 4, 2025
• Table 6 : List of Granted Patents in Neuroprotective Agent Field, 2022-2024
• Table 7 : Global Market for Neuroprotective Agents, by Indication, Through 2030
• Table 8 : Global Market for Neuroprotective Agents for Cerebrovascular Disease, by Region, Through 2030
• Table 9 : Global Market for Neuroprotective Agents for Neurodegenerative Disorders, by Type, Through 2030
• Table 10 : Global Market for Neuroprotective Agents for Neurodegenerative Disorders, by Region, Through 2030
• Table 11 : Global Market for Neuroprotective Agents for Ophthalmic Diseases, by Type, Through 2030
• Table 12 : Global Market for Neuroprotective Drugs for Ophthalmic Diseases, by Region, Through 2030
• Table 13 : Global Market for Neuroprotective Drugs for CNS Injury, by Region, Through 2030
• Table 14 : Global Market for Neuroprotective Agents, by Therapy Type, Through 2030
• Table 15 : Global Market for Neuroprotective Agents, by Drug Class, Through 2030
• Table 16 : List of a Few ASOs as Neuroprotective Agents
• Table 17 : Global Market for Neuroprotective Agents, by Region, Through 2030
• Table 18 : North American Market for Neuroprotective Agents, by Indication, Through 2030
• Table 19 : North American Market for Neuroprotective Agents, by Country, Through 2030
• Table 20 : U.S. Market for Neuroprotective Agents, by Indication, Through 2030
• Table 21 : Canadian Market for Neuroprotective Agents, by Indication, Through 2030
• Table 22 : Mexican Market for Neuroprotective Agents, by Indication, Through 2030
• Table 23 : European Market for Neuroprotective Agents, by Indication, Through 2030
• Table 24 : European Market for Neuroprotective Agents, by Country, Through 2030
• Table 25 : German Market for Neuroprotective Agents, by Indication, Through 2030
• Table 26 : U.K. Market for Neuroprotective Agents, by Indication, Through 2030
• Table 27 : French Market for Neuroprotective Agents, by Indication, Through 2030
• Table 28 : Spanish Market for Neuroprotective Agents, by Indication, Through 2030
• Table 29 : Italian Market for Neuroprotective Agents, by Indication, Through 2030
• Table 30 : Rest of Europe Market for Neuroprotective Agents, by Indication, Through 2030
• Table 31 : Asia-Pacific Market for Neuroprotective Agents, by Indication, Through 2030
• Table 32 : Asia-Pacific Market for Neuroprotective Agents, by Country, Through 2030
• Table 33 : Chinese Market for Neuroprotective Agents, by Indication, Through 2030
• Table 34 : Japanese Market for Neuroprotective Agents, by Indication, Through 2030
• Table 35 : Indian Market for Neuroprotective Agents, by Indication, Through 2030
• Table 36 : Rest of Asia-Pacific Market for Neuroprotective Agents, by Indication, Through 2030
• Table 37 : South American Market for Neuroprotective Agents, by Indication, Through 2030
• Table 38 : South American Market for Neuroprotective Agents, by Country, Through 2030
• Table 39 : Brazilian Market for Neuroprotective Agents, by Indication, Through 2030
• Table 40 : Argentine Market for Neuroprotective Agents, by Indication, Through 2030
• Table 41 : Rest of South American Market for Neuroprotective Agents, by Indication, Through 2030
• Table 42 : MEA Market for Neuroprotective Agents, by Indication, Through 2030
• Table 43 : MEA Market for Neuroprotective Agents, by Country, Through 2030
• Table 44 : Middle Eastern Market for Neuroprotective Agents, by Indication, Through 2030
• Table 45 : African Market for Neuroprotective Agents, by Indication, Through 2030
• Table 46 : Few Recent Strategic Initiatives, 2024-2025
• Table 47 : ESG Risk Rankings for Pharmaceutical Companies, 2023*
• Table 48 : Information Sources Used in this Report
• Table 49 : Abbreviations Used in this Report
• Table 50 : AbbVie Inc.: Company Snapshot
• Table 51 : AbbVie Inc.: Financial Performance, FY 2023 and 2024
• Table 52 : AbbVie Inc.: Product Portfolio
• Table 53 : AbbVie Inc: News/Key Developments, 2023 - 2024
• Table 54 : AstraZeneca: Company Snapshot
• Table 55 : AstraZeneca: Financial Performance, FY 2023 and 2024
• Table 56 : AstraZeneca: Product Portfolio
• Table 57 : AstraZeneca: News/Recent Developments, 2025
• Table 58 : Bayer AG: Company Snapshot
• Table 59 : Bayer AG: Financial Performance, FY 2022 and 2023
• Table 60 : Bayer AG: Product Portfolio
• Table 61 : Bayer AG: News/Key Developments, 2025
• Table 62 : Biogen.: Company Snapshot
• Table 63 : Biogen: Financial Performance, FY 2023 and 2024
• Table 64 : Biogen: Product Portfolio
• Table 65 : Biogen: News/Key Developments, 2023-2025
• Table 66 : Boehringer Ingelheim International GmbH: Company Snapshot
• Table 67 : Boehringer Ingelheim International GmbH: Financial Performance, FY 2023 and 2024
• Table 68 : Boehringer Ingelheim International GmbH: Product Portfolio
• Table 69 : Boehringer Ingelheim International GmbH: News/Key Developments, 2024
• Table 70 : Bristol-Myers Squibb Co.: Company Snapshot
• Table 71 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
• Table 72 : Bristol-Myers Squibb Co.: Product Portfolio
• Table 73 : Bristol-Myers Squibb Co.: News/Key Developments, 2023-2025
• Table 74 : Daiichi Sankyo Co. Ltd.: Company Snapshot
• Table 75 : Daiichi Sankyo Co. Ltd.: Financial Performance, FY 2023 and 2024
• Table 76 : Daiichi Sankyo Co. Ltd.: Product Portfolio
• Table 77 : F. Hoffmann-La Roche Ltd.: Company Snapshot
• Table 78 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
• Table 79 : F. Hoffmann-La Roche Ltd.: Product Portfolio
• Table 80 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023-2025
• Table 81 : GSK plc: Company Snapshot
• Table 82 : GSK plc.: Financial Performance, FY 2023 and 2024
• Table 83 : GSK plc: Product Portfolio
• Table 84 : GSK plc: News/Key Developments, 2025
• Table 85 : Lilly USA LLC.: Company Snapshot
• Table 86 : Lilly USA LLC.: Financial Performance, FY 2023 and 2024
• Table 87 : Lilly USA LLC.: Product Portfolio
• Table 88 : Lilly USA LLC.: News/Key Developments, 2024
• Table 89 : Merck & Co. Inc.: Company Snapshot
• Table 90 : Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
• Table 91 : Merck & Co. Inc.: Product Portfolio
• Table 92 : Merck & Co. Inc.: News/Key Developments, 2023
• Table 93 : Novartis AG: Company Snapshot
• Table 94 : Novartis AG: Financial Performance, FY 2023 and 2024
• Table 95 : Novartis AG: Product Portfolio
• Table 96 : Novartis AG: News/Key Developments, 2022-2025
• Table 97 : Sanofi: Company Snapshot
• Table 98 : Sanofi: Financial Performance, FY 2023 and 2024
• Table 99 : Sanofi: Product Portfolio
• Table 100 : Sanofi: News/Key Developments, 2025
• Table 101 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
• Table 102 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2023 and 2024
• Table 103 : Teva Pharmaceutical Industries Ltd.: Product Portfolio
• Table 104 : Teva Pharmaceutical Industries Ltd.: News/Key Developments, 2021-2023
• Table 105 : UCB S.A.: Company Snapshot
• Table 106 : UCB S.A.: Financial Performance, FY 2022 and 2023
• Table 107 : UCB S.A.: Product Portfolio
• Table 108 : UCB S.A.: News/Key Developments, 2024
• Table 109 : List of Few Emerging Startups in the Neuroprotective Agents Market

List of Figures

• Summary Figure : Global Market Shares of Neuroprotective Agents, by Region, 2024
• Figure 1 : PESTLE Analysis
• Figure 2 : Porter's Five Forces Analysis
• Figure 3 : Market Dynamics Snapshot of Neuroprotective Agents
• Figure 4 : Global Burden of Conditions Affecting the Nervous System, 2021
• Figure 5 : Breakdown of People Aging 65 or Older with Alzheimer's Dementia, 2025
• Figure 6 : Emerging Technologies in Neuroprotective Agents Market
• Figure 7 : Pipeline Analysis of Few Neurology Drugs, by Phases, 2025
• Figure 8 : Granted Patents vs. Patents Application, 2022-2025
• Figure 9 : Global Market Shares of Neuroprotective Agents, by Indication, 2024
• Figure 10 : Global Market Shares of Neuroprotective Agents for Cerebrovascular Disease, by Region, 2024
• Figure 11 : Global Market Shares of Neuroprotective Agents for Neurodegenerative Disorders, by Type, 2024
• Figure 12 : Global Market Shares of Neuroprotective Agents for Neurodegenerative Disorders, by Region, 2024
• Figure 13 : Global Market Shares of Neuroprotective Agents for Ophthalmic Diseases, by Type, 2024
• Figure 14 : Global Market Shares of Neuroprotective Drugs for Ophthalmic Diseases, by Region, 2024
• Figure 15 : Global Market Shares of Neuroprotective Drugs for CNS Injury, by Region, 2024
• Figure 16 : Global Market Shares of Neuroprotective Agents, by Therapy Type, 2024
• Figure 17 : Global Market Shares of Neuroprotective Agents, by Drug Class, 2024
• Figure 18 : Global Market Shares of Neuroprotective Agents, by Region, 2024
• Figure 19 : North American Market Shares of Neuroprotective Agents, by Indication, 2024
• Figure 20 : North American Market Shares of Neuroprotective Agents, by Country, 2024
• Figure 21 : U.S. Market Shares of Neuroprotective Agents, by Indication, 2024
• Figure 22 : Canadian Market Shares of Neuroprotective Agents, by Indication, 2024
• Figure 23 : Mexican Market Shares of Neuroprotective Agents, by Indication, 2024
• Figure 24 : European Market Shares of Neuroprotective Agents, by Indication, 2024
• Figure 25 : European Market Shares of Neuroprotective Agents, by Country, 2024
• Figure 26 : German Market Shares of Neuroprotective Agents, by Indication, 2024
• Figure 27 : U.K. Market Shares of Neuroprotective Agents, by Indication, 2024
• Figure 28 : French Market Shares of Neuroprotective Agents, by Indication, 2024
• Figure 29 : Spanish Market Shares of Neuroprotective Agents, by Indication, 2024
• Figure 30 : Italian Market Shares of Neuroprotective Agents, by Indication, 2024
• Figure 31 : Rest of Europe Market Shares of Neuroprotective Agents, by Indication, 2024
• Figure 32 : Asia-Pacific Market Shares of Neuroprotective Agents, by Indication, 2024
• Figure 33 : Asia-Pacific Market Shares of Neuroprotective Agents, by Country, 2024
• Figure 34 : Chinese Market Shares of Neuroprotective Agents, by Indication, 2024
• Figure 35 : Japanese Market Shares of Neuroprotective Agents, by Indication, 2024
• Figure 36 : Indian Market Shares of Neuroprotective Agents, by Indication, 2024
• Figure 37 : Rest of Asia-Pacific Market Shares of Neuroprotective Agents, by Indication, 2024
• Figure 38 : South American Market Shares of Neuroprotective Agents, by Indication, 2024
• Figure 39 : South American Market Shares of Neuroprotective Agents, by Country, 2024
• Figure 40 : Brazilian Market Shares of Neuroprotective Agents, by Indication, 2024
• Figure 41 : Argentine Market Shares of Neuroprotective Agents, by Indication, 2024
• Figure 42 : Rest of South American Market Shares of Neuroprotective Agents, by Indication, 2024
• Figure 43 : MEA Market Shares of Neuroprotective Agents, by Indication, 2024
• Figure 44 : MEA Market Shares of Neuroprotective Agents, by Country, 2024
• Figure 45 : Middle Eastern Market Shares of Neuroprotective Agents, by Indication, 2024
• Figure 46 : African Market Shares of Neuroprotective Agents, by Indication, 2024
• Figure 47 : Global Market Shares of Neuroprotective Agents, by Company, 2024
• Figure 48 : AbbVie Inc.: Revenue Shares, by Country/Region, FY 2024
• Figure 49 : AstraZeneca: Revenue Shares, by Business Unit, FY 2024
• Figure 50 : AstraZeneca: Revenue Shares, by Region/Country, FY 2024
• Figure 51 : Bayer AG: Revenue Shares, by Business Unit, FY 2024
• Figure 52 : Bayer AG: Revenue Shares, by Country/Region, FY 2024
• Figure 53 : Biogen: Revenue Shares, by Country/Region, FY 2024
• Figure 54 : Boehringer Ingelheim International GmbH: Revenue Shares, by Business Unit, FY 2024
• Figure 55 : Boehringer Ingelheim International GmbH: Revenue Shares, by Region/Country, FY 2024
• Figure 56 : Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2024
• Figure 57 : Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2024
• Figure 58 : Daiichi Sankyo Co. Ltd.: Revenue Shares, by Business Unit, FY 2024
• Figure 59 : Daiichi Sankyo Co. Ltd.: Revenue Shares, by Country/Region, FY 2024
• Figure 60 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2024
• Figure 61 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2023
• Figure 62 : GSK plc: Revenue Shares, by Business Unit, FY 2024
• Figure 63 : GSK plc: Revenue Shares, by Country/Region, FY 2024
• Figure 64 : Lilly USA LLC.: Revenue Shares, by Country/Region, FY 2024
• Figure 65 : Merck & Co. Inc.: Revenue Shares, by Business Unit, FY 2024
• Figure 66 : Merck & Co. Inc.: Revenue Shares, by Country/Region, FY 2024
• Figure 67 : Novartis AG: Revenue Shares, by Business Unit, FY 2024
• Figure 68 : Novartis AG: Revenue Shares, by Country/Region, FY 2023
• Figure 69 : Sanofi: Revenue Shares, by Country/Region, FY 2024
• Figure 70 : Teva Pharmaceutical Industries Ltd.: Revenue Shares, by Business Unit, FY 2024
• Figure 71 : Teva Pharmaceutical Industries Ltd.: Revenue Shares, by Country/Region, FY 2024
• Figure 72 : UCB S.A.: Revenue Shares, by Country/Region, FY 2024